Oppenheimer Upgrades Sarepta Therapeutics (SRPT) to Outperform

Oppenheimer analyst Hartaj Singh upgraded Sarepta Therapeutics (NASDAQ: SRPT) from Perform to Outperform with a price target of $180.00.

For an analyst ratings summary and ratings history on Sarepta Therapeutics click here. For more ratings news on Sarepta Therapeutics click here.

Shares of Sarepta Therapeutics closed at $131.70 yesterday.

You May Also Be Interested In

• Northland Upgrades Hyliion Holdings (HYLN) to Outperform 'on Improved Visibility to KARNO Commercialization'
• Wolfe Research Upgrades Abbott Labs (ABT) to Outperform
• Macquarie Upgrades Inventec Corp (2356:TT) to Neutral